Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP)

NCT04883905 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.

NCT NCT04883905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04883905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP)
Lead sponsor
Alnylam Pharmaceuticals
Phase
Observational
Overall status
Recruiting
Start date
April 26, 2021
Completion date
December 31, 2030
Enrollment
150 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

acute hepatic porphyria